522 citations,
January 2001 in “Cancer investigation” Doxil is an effective, modified chemotherapy drug with a unique toxicity profile and shows promise in treating certain cancers.
81 citations,
February 2000 in “Anti-cancer drugs” Doxil showed some effectiveness against advanced prostate cancer but caused severe side effects at higher doses.
32 citations,
May 2018 in “Journal of the American Academy of Dermatology” Skin reactions from cancer treatments might predict how well the treatments work.
18 citations,
January 2017 in “Postępy Dermatologii i Alergologii” EGFR inhibitors can cause various skin issues during cancer treatment, and managing these is important for patient care.
7 citations,
August 2017 in “Journal of dermatological science” Sorafenib causes skin reactions by increasing the number and activity of skin mast cells.